Dr Jie Tang is an NHMRC Emerging Leadership Fellow, who has expertise in biomedical engineering, pharmaceutics and nanotechnology. Her research endeavors encompass both fundamental and applied research at the nano-bio interface through nanomaterial innovation. Specifically, Dr Tang's group is dedicated to develop nanoparticle-based platforms tailored for drug and gene delivery, cancer immunotherapy and vaccine adjuvants, leveraging the nanoparticles' unique nanostructure and surface chemistry. 

Since completing her PhD at UQ in 2018, Dr Tang has secured research grants as CI totalling over AU$ 2.3 million and etabilished licensing aggreements with industry partners like AstraZeneca.

Joining D4, MIPS in fall 2023, Dr Tang aims to collaborate with fellow researchers to explore the interaction between nanoparticles and biological barriers, optimizing their efficacy for therapeutic and vaccine purposes.

• Engineering biomimetic nanoplatform for oral delivery of large biomolecules (ie, mRNA/pDNA/siRNA/protein);
• Nanoparticle-based vaccine adjuvants (Nanoadjuvants);
• Nanomaterials-based cancer immunotherapy;
• Orally delivered nanovaccines for preventing cancer relapse.